Published January 1, 2020 | Version v1
Journal article Open

Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study

  • 1. Hacettepe Univ, Dept Pediat Neurol, Ankara, Turkey
  • 2. Marmara Univ, Fac Pharm, Istanbul, Turkey
  • 3. Analyt Chem, Istanbul, Turkey
  • 4. Marmara Univ, Sch Appl Disciplines, Istanbul, Turkey
  • 5. Hacettepe Univ, Dept Radiol, Ankara, Turkey

Description

Background: Aprepitant is a neurokinin-1 receptor antagonist approved for the treatment of chemotherapy-induced nausea. We aimed to investigate the safety and efficacy of aprepitant in patients with subacute sclerosing panencephalitis.

Files

bib-da6c7153-8111-41c9-ad5b-cb4872136539.txt

Files (285 Bytes)

Name Size Download all
md5:02d467fff9213f55ccc884020ec31f26
285 Bytes Preview Download